Three Statutory Committee decisions “flawed”
Three Royal Pharmaceutical Society Statutory Committee decisions between April 2004 and March 2005 were flawed in the view of the Council for Healthcare Regulatory Excellence.
In one of the cases, involving a pharmacist with an alcohol problem,
a CHRE case review meeting resolved to ask the High Court to overturn
the Statutory Committee’s finding. But the decision was not implemented
because the Statutory Committee reopened the case and the pharmacist
agreed to stop practising (PJ, 18/25 December 2004, p895).
This information is revealed in a CHRE paper (PDF 100K) by Jonathan Montgomery,
professor of health law at Southampton University. It shows that each
of the other two cases gave cause for concern about the Society’s
regulatory practice. But they were not referred to the High Court because
the CHRE believed that it would achieve more by persuading the Society
to do things differently in future.
Mandie Lavin, director of fitness to practise and legal affairs at the
Society, said that there is little that the Society can do to influence
Statutory Committee decisions and that this is one of the profession’s
strengths. She added that the CHRE did not understand the Statutory Committee’s
independence.
“We’re keen to collaborate and co-operate with our external
regulator and are always looking to enhance the quality of decision-making,” she
said. “However, our committee is totally independent of the Society.
It is unique among health regulators in having a legally qualified chairman
and it includes no Council members.”
Expressing concern that the Statutory Committee’ strength could
be diminished by future regulatory changes, Mrs Lavin said that the planned
Section 60 Order that will modernise pharmacy regulation would remove
from the Privy Council the responsibility for appointing the chairman.
“Our ability to withstand scrutiny is strengthened by having a
Privy Council appointed chairman who, like a High Court judge, is beyond
influence.” |